Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Adult
Animals
Antineoplastic Agents
/ pharmacology
Biopsy
Bone Marrow
/ pathology
Bortezomib
/ pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Humans
Macrophages
/ pathology
Mice
Multiple Myeloma
/ drug therapy
Neoplastic Stem Cells
/ pathology
Proteasome Inhibitors
/ pharmacology
Recurrence
Young Adult
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
05
2019
revised:
09
07
2019
accepted:
07
08
2019
pubmed:
15
8
2019
medline:
29
7
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Multiple myeloma (MM) is a plasma cell neoplasia commonly treated with proteasome inhibitors such as bortezomib. Although bortezomib has demonstrated enhanced survival benefit, some patients relapse and subsequently develop resistance to such therapy. Here, we investigate the mechanisms underlying relapse and refractory MM following bortezomib treatment. We show that bortezomib-exposed proinflammatory macrophages promote an enrichment of MM-tumor-initiating cells (MM-TIC) both
Identifiants
pubmed: 31409628
pii: 1541-7786.MCR-19-0487
doi: 10.1158/1541-7786.MCR-19-0487
doi:
Substances chimiques
Antineoplastic Agents
0
Proteasome Inhibitors
0
Bortezomib
69G8BD63PP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2331-2340Informations de copyright
©2019 American Association for Cancer Research.